What is claimed is:

1. A stable pharmaceutical formulation comprising a bispecific antibody construct in an amount of at least 10 mg/mL, a buffer, a saccharide, and a surfactant, wherein the formulation has a pH of 4-6.

2. The formulation of claim 1, that is lyophilized.

3. The formulation of claim 1 or 2, that is stable for up to 3 months at 4^{o}C.

4. The formulation of any one of claims 1-3, wherein the formulation comprises less than 2% high molecular weight species after 3 months at 4^{o}C.

5. The formulation of any one of claims 1-4, wherein the formulation has a pH of 4-5.

6. The formulation of any one of claims 1-4, wherein the formulation has a pH of 4.2.

7. The formulation of any one of claims 1-6, wherein the buffer is an acetate buffer, a glutamate buffer, a citrate buffer, a lactic buffer, a succinate buffer, a tartrate buffer, a fumarate buffer, a maleate buffer, a histidine buffer, or a phosphate buffer.

8. The formulation of any one of claims 1-7, wherein the buffer is present at a concentration ranging from 5 to 200 mM.

9. The formulation of claim 8, wherein the buffer is present at a concentration ranging from 10 to 50 mM.

10. The formulation of any one of claims 1-9, wherein the saccharide is a monosaccharide or a disaccharide.

11. The formulation of any one of claims 1-10, wherein the saccharide is glucose, galactose, fructose, xylose, sucrose, lactose, maltose, trehalose, sorbitol, mannitol or xylitol.

12. The formulation of any one of claims 1-11, wherein the saccharide is present in a concentration ranging from 1 to 15% (w/v).

13. The formulation of claim 12, wherein the saccharide is present in a concentration ranging from 5 to 12% (w/v).

14. The formulation of claim 12, wherein the saccharide is present in a concentration ranging from 7 to 12% (w/v).

15. The formulation of any one of claims 1-154 wherein the surfactant is polysorbate 20, polysorbate 40, polysorbate 60, polysorbate 80, poloxamer 188, poloxamer 407, triton X-100, polyoxyethylene, PEG 3350, PEG 4000, or a combination thereof.

16. The formulation of any one of claims 1-15, wherein the surfactant is present in a concentration ranging from 0.001% to 0.5% (w/v).

17. The formulation of claim 16, wherein the surfactant is present in a concentration ranging from 0.001% to 0.01% (w/v).

18. The formulation of any one of claims 1-17, wherein the bispecific antibody construct is present in a concentration ranging from 10 mg/mL to 20 mg/mL.

19. The formulation of any one of claims 1-18, wherein the bispecific antibody construct is present in an amount of 20 mg/mL.

20. The formulation of any one of claims 1-19, wherein the formulation comprises 10 mM glutamate, 9% (w/V) sucrose and 0.01% (w/V) polysorbate 80, wherein the formulation has a pH of 4.2.

21. The formulation of any one of claims 1-20, wherein the bispecific antibody construct comprises a first binding domain that binds to a target cell surface antigen, a second binding domain that binds to human CD3 on the surface of a T cell.

22. The formulation of claim 21, wherein the bispecific antibody construct further comprises a third domain comprising, in an amino to carboxyl order, hinge-CH2 domain-CH3 domain-linker-hinge-CH2 domain-CH3 domain.

22. The formulation of claim 21, wherein each of the first and second binding domains comprise a VH region and a VL region.

23. The formulation of claim 21 or claim 22, wherein the bispecific antibody construct is a single chain antibody construct.

24. The formulation of any one of claims 21-23, wherein the target cell surface antigen is CDH19, MSLN, DLL3, FLT3, EGFR, EGFRvlll, BCMA, PSMA, CD33, CD19, CD70, MUC17 or CLDN18.2.

25. The formulation of any one of claims 21-24, wherein the first binding domain of the bispecific antibody construct comprises a set of 6 CDRs set forth in (a) SEQ ID NOs: 24-29, (b) SEQ ID NOs: 34-39, (c) SEQ ID NOs: 78-83, (d) SEQ ID NOs: 10-15, (e) SEQ ID NOs: 46-51, (f) SEQ ID NOs: 88-93, (g) SEQ ID NOs: 67-72, (h) SEQ ID NOs: 56-61, (i) SEQ ID NOs: 112-117, (j) SEQ ID NOs: 100-105, (k) SEQ ID NOs:148-153, SEQ ID NOs: 157-162, SEQ ID NOs: 166-171, or SEQ ID NOs: 175-180, (l) SEQ ID NOs:132-137, or (m) 123-128.

26. The formulation of any one of claims 21-25, wherein the second binding domain of the bispecific antibody construct comprises a set of 6 CDRs set forth in SEQ ID NOs: 1-6.

27. The formulation of any one of claims 21-26, wherein the first binding domain comprises:

(a) a VH region comprising an amino acid sequence set forth in SEQ ID NO: 30 and a VL region comprising an amino acid sequence set forth in SEQ ID NO: 31;

(b) a VH region comprising an amino acid sequence set forth in SEQ ID NO: 40 and a VL region comprising an amino acid sequence set forth in SEQ ID NO: 41;

(c) a VH region comprising an amino acid sequence set forth in SEQ ID NO: 84 and a VL region comprising an amino acid sequence set forth in SEQ ID NO: 85;

(d) a VH region comprising an amino acid sequence set forth in SEQ ID NO: 16 or 17 and a VL region comprising an amino acid sequence set forth in SEQ ID NO: 18 or 19;

(e) a VH region comprising an amino acid sequence set forth in SEQ ID NO: 52 and a VL region comprising an amino acid sequence set forth in SEQ ID NO: 53;

(f) a VH region comprising an amino acid sequence set forth in SEQ ID NO: 94 and a VL region comprising an amino acid sequence set forth in SEQ ID NO: 95;

(g) a VH region comprising an amino acid sequence set forth in SEQ ID NO: 73 and a VL region comprising an amino acid sequence set forth in SEQ ID NO: 74;

(h) a VH region comprising an amino acid sequence set forth in SEQ ID NO: 62 and a VL region comprising an amino acid sequence set forth in SEQ ID NO: 63;

(i) a VH region comprising an amino acid sequence set forth in SEQ ID NO: 118 and a VL region comprising an amino acid sequence set forth in SEQ ID NO: 119;

(j) a VH region comprising an amino acid sequence set forth in SEQ ID NO: 154, 163, 172 or 181 and a VL region comprising an amino acid sequence set forth in SEQ ID NO: 155, 164, 173 or 182;

(k) a VH region comprising an amino acid sequence set forth in SEQ ID NO: 106 and a VL region comprising an amino acid sequence set forth in SEQ ID NO: 107;

(l) a VH region comprising an amino acid sequence set forth in SEQ ID NO: 138 or 143 and a VL region comprising an amino acid sequence set forth in SEQ ID NO: 139 or 144; or

(m) a VH region comprising an amino acid sequence set forth in SEQ ID NO: 129 and a VL region comprising an amino acid sequence set forth in SEQ ID NO: 130.

28. The formulation of any one of claims 21-27, wherein the second binding domain comprises a VH region comprising an amino acid sequence set forth in SEQ ID NO: 7 and a VL region comprising an amino acid sequence set forth in SEQ ID NO: 8.

29. The formulation of any one of claims 21-28, wherein the bispecific antibody construct comprises amino acid sequence set forth in SEQ ID NO: 20, SEQ ID NO: 21, SEQ ID NO: 22, SEQ ID NO: 23, SEQ ID NO: 33, SEQ ID NO: 43, SEQ ID NO: 44, SEQ ID NO: 45, SEQ ID NO: 55, SEQ ID NO: 65, SEQ ID NO: 66, SEQ ID NO: 55, SEQ ID NO: 76, SEQ ID NO: 77, SEQ ID NO: 87, SEQ ID NO: 97, SEQ ID NO: 98, SEQ ID NO: 99, SEQ ID NO: 109, SEQ ID NO: 110, SEQ ID NO: 111, SEQ ID NO: 121, SEQ ID NO: 122, SEQ ID NO: 131, SEQ ID NO: 141, SEQ ID NO: 142, SEQ ID NO: 146, SEQ ID NO: 147, SEQ ID NO: 156, SEQ ID NO: 165, SEQ ID NO: 174, SEQ ID NO: 183, SEQ ID NO: 184, SEQ ID NO: 185, SEQ ID NO: 186, SEQ ID NO: 187, or SEQ ID NO: 188.

30. Use of the formulation of any one of claims 1-29 in the manufacture of a medicament for treating cancer in a subject in need.

31. A formulation of any one of claims 1-29 for use in therapy.